Working… Menu

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00389675
Recruitment Status : Terminated (Study DAR-312 did not meet its primary co-endpoints.)
First Posted : October 19, 2006
Last Update Posted : January 6, 2014
Information provided by (Responsible Party):
Gilead Sciences

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 2010
Actual Study Completion Date : May 2010
Certification/Extension First Submitted : January 3, 2014